Agilent Technologies

Metabolism Assays Research Report 2023: Market Analysis by Instruments, Assays Kits, Colorimetry, Fluorimetry, Spectrometry, Diagnostics, Research - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Biotechnology, Pharmaceutical, Health, Agilent Technologies, Abcam, Investment, Hospital, USD, Compound annual growth rate, Diabetes, Drug discovery, Diagnosis, Growth, Region, Colorimetry, ChromeOS, Merck Group, Thermo Fisher Scientific, Research report, Medical device, Fine chemical, Obesity, Spectrometry, Research

The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%

Key Points: 
  • The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%
    This research report categorizes the Metabolism Assays Market by product, technology, application, end-user, and region.
  • Nevertheless, concerns related to the high cost of metabolism assays act as a hindrance to market growth.
  • Moreover, the region benefits from a growing population afflicted with target diseases, further supporting the expansion of the metabolism assays market.
  • Additionally, the report covers aspects such as new product and service launches, mergers and acquisitions, and recent developments within the metabolism assays market.

Liquid Handling Technologies and Global Markets Report 2023: Revenue Data for 2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Technology, Other Technology, Mettler Toledo, Thermo Fisher Scientific, Research, Acquisition, Investment, Risk, Biotechnology, COVID-19, Automation, Drug discovery, Growth, Agilent Technologies, SE, ESG, Fine chemical, Pharmaceutical industry

The "Liquid Handling: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liquid Handling: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report will focus on liquid handling equipment for biological and chemical laboratory use and applications of the equipment.
  • The global market for liquid handling was valued at $4.2 billion in 2022.
  • This growth is driven by increased awareness of the importance of liquid handling and substantial investments in research and development focused on liquid handling for drug discovery and development.

Agilent Increases Cash Dividend to 23.6 Cents per Share

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Other Health, Health, Technology, Software, Agilent Technologies, NYSE, Holding company

Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend.
  • The quarterly dividend will be paid on Jan. 24, 2024, to all shareholders of record as of the close of business on Jan. 2, 2024.
  • The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, FDA, Medical Devices, Health, Oncology, MSD, HNSCC, PD-L1, Trastuzumab, NYSE, Cervical cancer, Head, Incidence, Patient, Triple-negative breast cancer, Agilent Technologies, Stomach cancer, Stomach, Pembrolizumab, Lung cancer, PD-1, Adenocarcinoma, Partnership, ESCC, Cancer, Merck & Co., Physician, CPS, GEJ, TNBC, NSCLC, Pharmaceutical industry, Vaccine, Merck

Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
  • PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic that can identify gastric or GEJ adenocarcinoma patients suitable for treatment with KEYTRUDA in combination with chemotherapy and trastuzumab plus fluoropyrimidine.
  • This marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval.
  • PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck (known as MSD outside the United States and Canada) as a companion diagnostic for KEYTRUDA.

Agilent Announces Thought Leader Award to Professor Jennifer Field

Retrieved on: 
Monday, November 13, 2023
Software, Research, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, Technology, Science, Telecommunications, Other Science, External, Associate, NYSE, Groundwater, PFAS, Risk, Agilent Technologies, Oregon State University, Health, Agricultural science, Biophysical environment, Fluorine, Management, Environmental remediation

Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award.
  • Professor Field commented on the Agilent Thought Leader Award.
  • Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry division, remarked on the significance of recognizing Professor Field with this award.
  • For more information, please visit the Agilent Thought Leader Award website.

BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual Meeting

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, MSI, WES, TMB, American Securities, Salt Palace, Sequence, Epigenome-wide association study, Molecular diagnostics, Agilent Technologies, Journal, HRD, Chromosomal translocation, R, Molecular reference standards, AMP, Abstract (summary)

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.
  • During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.
  • Details of BostonGene’s presence at AMP are below:
    Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene
    Tumor molecular characterization is key for advancing precision oncology.
  • In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses.

First Tech Federal Credit Union Finds People in Tech Carry 45% Less Credit Card Debt than Members in Other Industries

Retrieved on: 
Wednesday, December 13, 2023
Negotiation, SAN, HP Inc., Nike, Agilent Technologies, Cisco, Intel, Thumb, Housing, Microsoft, Cryptocurrency, Bank, Amazon, Intuit

SAN JOSE, Calif. and HILLSBORO, Ore., Dec. 13, 2023 /PRNewswire-PRWeb/ -- This year, technology layoffs have surged past 240,000 globally, a 50% increase from 2022, but new data suggests people working in tech are managing finances more effectively, according to First Tech Federal Credit Union, the banking partner for tech innovators. The new insights are based on an analysis of First Tech's nearly 700,000 members, including many people working in the tech industry. The data shows tech-based members have 45% less in credit card debt than their non-tech counterparts - and while credit card balances for non-tech members are up 25% year-over-year, tech-based members only saw a 4% increase in credit card balances during the same period.

Key Points: 
  • The new insights are based on an analysis of First Tech's nearly 700,000 members, including many people working in the tech industry.
  • The data shows tech-based members have 45% less in credit card debt than their non-tech counterparts - and while credit card balances for non-tech members are up 25% year-over-year, tech-based members only saw a 4% increase in credit card balances during the same period.
  • The data shows tech-based members have 45% less in credit card debt than their non-tech counterparts - and while credit card balances for non-tech members are up 25% year-over-year, tech-based members only saw a 4% increase in credit card balances during the same period.
  • However, tech members show healthier balances, with 167% more in their checking accounts than non-tech members, with an average balance of over $16,548.

In-vitro Diagnostics Market to grow by USD 33.16 billion from 2021 to 2026 | The rising geriatric population with chronic and infectious diseases drives the market growth - Technavio

Retrieved on: 
Wednesday, December 13, 2023
Abbott Laboratories, Sample, Thermo Fisher Scientific, Prevalence, DiaSorin, Immunoassay, ROW, Hepatitis B virus, BGI Group, Laboratory, Patient, HBV, Mindful Scientific Inc., Danaher Corporation, Infection, Illumina, Inc., Quest Diagnostics, Virus, Cancer, Ageing, HCV, QIAGEN, IVD, Diabetes, Agilent Technologies, Retail, Medical device, Hematology, Geography

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.

Key Points: 
  • NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.
  • The rising geriatric population with chronic and infectious diseases drives the in-vitro diagnostics (IVD) market growth during the forecast period.
  • Hence, the increasing prevalence of diseases in the aging population is expected to drive market growth during the forecast period.
  • Key challenges - Stringent regulatory guidelines for in-vitro diagnostics manufacturers can pose a significant threat which can hinder the in-vitro diagnostics (IVD) market growth during the forecast period.

PFAS Testing Market Worth $121 Million | MarketsandMarkets

Retrieved on: 
Monday, December 11, 2023
Waters Corporation, PFAS, Privatization, HPLC, Research, PerkinElmer, Drinking water, Service, Pollution, Pulse, R, Growth, Agilent Technologies, Shimadzu, Merck Group, Cosmetics, Marketing

Key Market Players of PFAS Testing Industry:

Key Points: 
  • Key Market Players of PFAS Testing Industry:
    As of 2022, prominent players in PFAS testing are Merck KGaA (Germany), Agilent Technologies (US), LGC Limited (UK), Waters Corporation (US), Biotage (Sweden), AccuStandard, Inc. (US), PerkinElmer, Inc. (US), Thermo Fisher Scientific, Inc. (US), Phenomenex (US), MACHEREY-NAGEL GmbH & Co. KG (Germany), and Shimadzu Corporation (Japan), among others.
  • In June 2022, MACHEREY-NAGEL GmbH & Co. KG introduced NUCLEODUR PFAS and PFAS Delay, HPLC columns for the analysis of per- and polyfluoroalkyl substances (PFAS).
  • PFAS Testing Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

PFAS Testing Market Worth $121 Million | MarketsandMarkets

Retrieved on: 
Monday, December 11, 2023
Waters Corporation, PFAS, Privatization, HPLC, Research, PerkinElmer, Drinking water, Service, Pollution, Pulse, R, Growth, Agilent Technologies, Shimadzu, Merck Group, Cosmetics, Marketing

Key Market Players of PFAS Testing Industry:

Key Points: 
  • Key Market Players of PFAS Testing Industry:
    As of 2022, prominent players in PFAS testing are Merck KGaA (Germany), Agilent Technologies (US), LGC Limited (UK), Waters Corporation (US), Biotage (Sweden), AccuStandard, Inc. (US), PerkinElmer, Inc. (US), Thermo Fisher Scientific, Inc. (US), Phenomenex (US), MACHEREY-NAGEL GmbH & Co. KG (Germany), and Shimadzu Corporation (Japan), among others.
  • In June 2022, MACHEREY-NAGEL GmbH & Co. KG introduced NUCLEODUR PFAS and PFAS Delay, HPLC columns for the analysis of per- and polyfluoroalkyl substances (PFAS).
  • PFAS Testing Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.